InMode Ltd. remains a global leader in minimally-invasive aesthetics, with proprietary RF and laser technologies and a strong international growth trajectory. I maintain a Strong Buy rating for INMD, citing undervaluation, robust free cash flow, a fortress balance sheet, and aggressive share repurchases. U.S. market saturation and sales execution remain challenges, but leadership changes and new product launches are driving positive cultural and operational shifts.
InMode Ltd. (INMD) Q1 2026 Earnings Call Transcript
InMode Ltd. (NASDAQ: INMD - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $12.76, but opened at $13.71. InMode shares last traded at $13.5850, with a volume of 653,419 shares changing hands. Wall Street Analysts Forecast Growth A number of research firms have recently weighed in on
| Health Care Technology Industry | Healthcare Sector | Moshe Mizrahy CEO | XSTU Exchange | IL0011595993 ISIN |
| IL Country | 660 Employees | - Last Dividend | 1 Oct 2021 Last Split | 8 Aug 2019 IPO Date |
InMode Ltd. is a pioneering company known for its design, development, manufacturing, and international marketing of innovatively minimally invasive aesthetic medical products. Leveraging proprietary technologies like radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency, InMode aims to offer advanced solutions for a variety of aesthetic medical procedures. Originating as Invasix Ltd., the company undertook a rebranding initiative, adopting the name InMode Ltd. in November 2017. Since its incorporation in 2008, with headquarters based in Yokneam, Israel, InMode has dedicated itself to improving patient outcomes and experiences in the aesthetic medicine field through its diverse product range, serving both the domestic market in the United States and global clients.
InMode's product portfolio is distinguished by a wide array of minimally invasive and non-invasive medical aesthetic solutions targeting an extensive range of procedures and conditions: